Dyadic International Inc. (DYAI)
| Bid | 1.19 |
| Market Cap | 36.71M |
| Revenue (ttm) | 3.5M |
| Net Income (ttm) | -5.81M |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -6.1 |
| Forward PE | -5.37 |
| Analyst | Buy |
| Ask | 1.26 |
| Volume | 13,724 |
| Avg. Volume (20D) | 43,247 |
| Open | 1.23 |
| Previous Close | 1.24 |
| Day's Range | 1.21 - 1.24 |
| 52-Week Range | 0.93 - 2.67 |
| Beta | 0.97 |
About DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific anti...
Analyst Forecast
According to 1 analyst ratings, the average rating for DYAI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 391.80% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call TranscriptDyadic International, Inc. (NASDAQ:DYAI ) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Execut...